Gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis: safety, efficacy and patient perspective [0.03%]
格拉司琼滴眼液治疗细菌性结膜炎：安全性、有效性及患者的视角
Clyde Schultz
Clyde Schultz
Gatifloxacin is a fourth generation fluroquinolone antibiotic that has been prescribed for systemic use. However, the drug which was developed by Kyorin (Japan) was linked to toxic reactions and death and was banned in the United States and...
Laura Crawley,Sohaib M Zamir,Maria F Cordeiro et al.
Laura Crawley et al.
Elevated IOP in clinical practice is usually seen in glaucoma or ocular hypertension. Glaucoma affects 60 million people worldwide and 8.4 million are bilaterally blind from this chronic disease.1 Options for reducing IOP rely on pharmacolo...
Oculo-Visual Findings among Industrial Mine Workers at Goldfields Ghana Limited, Tarkwa [0.03%]
戈尔德菲尔兹有限公司塔克瓦金矿工的眼和视觉发现
Go Ovenseri-Ogbomo,S Ocansey,Ek Abu et al.
Go Ovenseri-Ogbomo et al.
Objective: The focus of this study was to evaluate the visual status of mine workers who were directly involved in mining and/or are exposed to the mining environment. ...
Acute Herpetic Keratitis: What is the Role for Ganciclovir Ophthalmic Gel? [0.03%]
急性疱疹性角膜炎：更昔洛韦眼用凝胶的作用是什么？
Afsun Sahin,Pedram Hamrah
Afsun Sahin
Herpes simplex keratitis (HSK) is a major cause of corneal blindness in the world. Following the primary infection, the virus enters into a latent phase. Recurrent infectious or immune keratitis cause structural damage to the cornea, scarri...
Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion [0.03%]
玻璃体腔内注射兰比珠单抗治疗视网膜静脉阻塞黄斑水肿的安全性和疗效
Roberto Gallego-Pinazo,Rosa Dolz-Marco,Cristina Marín-Lambíes et al.
Roberto Gallego-Pinazo et al.
Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by rand...
Review of Azithromycin Ophthalmic 1% Solution (AzaSite(®)) for the Treatment of Ocular Infections [0.03%]
阿昔洛韦眼用溶胶（AzaSite(®)）治疗眼部感染的疗效及安全性系统评价和 meta 分析
Dominick L Opitz,Jennifer S Harthan
Dominick L Opitz
AzaSite(®) (azithromomycin 1.0%) ophthalmic solution was approved in 2007 by the US Food and Drug Administration (FDA) as the first commercially available formulation of ophthalmic azithromycin for the treatment of bacterial conjunctivitis...
Evolution of Cellular Inclusions in Bietti's Crystalline Dystrophy [0.03%]
Bietti晶状体 dystrophy的细胞内包涵体演变
Emiko Furusato,J Douglas Cameron,Chi-Chao Chan
Emiko Furusato
Bietti's crystalline dystrophy (BCD) consists of small, yellow-white, glistening intraretinal crystals in the posterior pole, tapetoretinal degeneration with atrophy of the retinal pigment epithelium (RPE) and "sclerosis" of the choroid; in...
Jared E Knickelbein,Simon C Watkins,Paul G McMenamin et al.
Jared E Knickelbein et al.
The composition and location of professional antigen presenting cells (APC) varies in different mucosal surfaces. The cornea, long considered an immune-privileged tissue devoid of APCs, is now known to host a heterogeneous network of bone m...
Diabetes Accelerates Retinal Neuronal Cell Death In A Mouse Model of Endogenous Hyperhomocysteinemia [0.03%]
糖尿病加速内源性高同型半胱氨酸小鼠视网膜神经细胞死亡
Preethi S Ganapathy,Penny Roon,Tracy K V E Moister et al.
Preethi S Ganapathy et al.
Hyperhomocysteinemia has been implicated in visual dysfunction. We reported recently that mice with endogenous hyperhomocysteinemia, due to mutation of the cystathionine-β-synthase (cbs) gene, demonstrate loss of neurons in the retinal gan...
Early Involvement of Immune/Inflammatory Response Genes in Retinal Degeneration in DBA/2J Mice [0.03%]
在DBA/2J小鼠视网膜退变早期阶段免疫及炎症反应基因的参与作用
W Fan,X Li,W Wang et al.
W Fan et al.
PURPOSE: The DBA/2J (D2) mouse carries mutations in two of its genes, Tyrp1 and Gpnmb. These alterations result in the development of an immune response in the iris, leading to iris atrophy and pigment dispersion. The development of elevate...